Optimization of Pharmaceutical R&D Programs and Portfolios

Design and Investment Strategy

Inbunden, Engelska, 2014

2 699 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

Some development strategies that are discussed are indication sequencing, optimal number of programs and optimal decision criteria.This book includes chapters written by authors with very broad backgrounds including financial, clinical, statistical, decision sciences, commercial and regulatory.

Produktinformation

Utgivningsdatum2014-10-27
Mått155 x 235 x 15 mm
Vikt446 g
FormatInbunden
SpråkEngelska
Antal sidor202
Upplaga2015
FörlagSpringer International Publishing AG
ISBN9783319090740

Tillhör följande kategorier

Zoran Antonijevic is a Senior Director at Cytel Consulting with responsibility for strategic advice at trial, program, or portfolio level. His research areas include: adaptive design, pharmaceutical portfolio optimization, and decision-making within clinical drug development process. Zoran has 20 years of experience in drug development. His prior experience includes positions at Harvard School of Public Health, GlaxoSmithKline, and Quintiles Innovation where his primary responsibility was to develop designs and approaches that maximize probability of success for programs and/or maximize product's value. He also has extensive experience with performing due-diligence, and as a member of product portfolio executive teams. Externally, Zoran is the chair of DIA Adaptive Design Scientific Working Group.

Need for Optimal Design of Pharmaceutical Programs and Portfolios in Modern Medical Product Development.- Clinical Aspects of Pharmaceutical Portfolio Management.- Drug Development and the Cost of Capital.- Investment Considerations for Pharmaceutical Product Portfolios.- Challenges of Portfolio Management in Pharmaceutical Development.- Impact of Phase 2b Strategies on Optimization of Drug Development Programs.- Using Decision Analysis to Support the Design of Clinical Trials at a Program Level.- Indication Sequencing for a New Molecular Entity with Multiple Potential Oncology Indications.- Maximizing Return on Investment in Phase II Proof-of-Concept Trials.- Portfolio Optimization of Therapies and Their Predictive Biomarkers.- Dynamically Optimizing Budget Allocation for Phase 3 Drug Development Portfolios Incorporating Uncertainty in the Pipeline.